93results about How to "Increase apoptosis rate" patented technology

The invention provides an FPGA (field programmable gate array) control-based all-solid-state high-voltage nanosecond pulse generator, and belongs to the field of bio-electromagnetic technology. The nanosecond pulse generator mainly comprises a power supply system, a pulse forming system, a pulse measurement system, an FPGA control system, a signal conversion system and a portable computer. In the generator, the output pulse amplitude is between 0 and 10kV, the pulse width is between 200 and 1000ns, the pulse frequency is between 1 and 1000Hz, the falling edge is between 30 and 40ns, the number of pulse is between 1 and 1000, and particular parameters are determined according the requirement of tumor treatment. The FPGA control-based all-solid-state high-voltage nanosecond pulse generator has the characteristics of intelligent regulation of pulse parameters (pulse amplitude, width, frequency and number), optical fiber transmission, high parameter accuracy, long service life, small size, low failure rate, good security and the like; and the generator outputs high pulse frequency, and is advantageous to quick searching of the optimal window parameters for inducing tumor cell apoptosis by virtue of intelligent regulation, so that the tumor treatment effect is improved. The FPGA control-based all-solid-state high-voltage nanosecond pulse generator can be widely applied to tumor treatment.

The invention relates to a portable high-voltage nanosecond squarer which belongs to a medicinal device for inducing cancer cell apoptosis by using a high-voltage nanosecond square wave pulse electric field. The portable high-voltage nanosecond squarer mainly comprises a power supply system, a high-voltage direct current module, a low-voltage power supply, a pulse forming system and a pulse shaping and counting system. The portable high-voltage nanosecond squarer has output pulses with highest amplitude of 15kV, pulse width adjustment range of 50ns-1us, rising edge gradient of reaching 10ns and controllable recurrence frequency of 0.2-15Hz; and the quantity of the output pulses of the portable high-voltage nanosecond squarer can be set. The portable high-voltage nanosecond squarer can be adjusted in multiple-parameters (pulse amplitude, pulse width, recurrence frequency, pulse quantity and the like), large-range and flexible and independent way, and is beneficial to researching the optimal window parameter of the cancer cell apoptosis and promoting the cancer cell apoptosis as well as improving the cancer treatment effect. Meanwhile, the portable high-voltage nanosecond squarer has compact and light structure, reliable work, simple operation and convenient popularization and application, and can be widely applied to the treatment of various cancers.

The invention relates to a preparation method of coix seed polysaccharide. The preparation method comprises the following steps of: crushing and screening coix seeds first, and carrying out degreasing, water bath extraction, centrifugation, enzymolysis, concentration, alcohol precipitation and vacuum freeze drying and precipitation to obtain crude coix seed polysaccharide; and dissolving the prepared crude coix seed polysaccharide to obtain a crude coix seed polysaccharide solution, carrying out deproteinization, decoloration, dialysis and ion exchange chromatography on the crude coix seed polysaccharide solution to obtain purified coix seed polysaccharide, and then carrying out vacuum freeze drying to obtain white powder, namely the coix seed polysaccharide. According to the preparation method disclosed by the invention, the crude coix seed polysaccharide is extracted by using a water extraction and alcohol precipitation method, the crude coix seed polysaccharide is subjected to deproteinization, decoloration, dialysis and ion exchange chromatography to obtain the purified coix seed polysaccharide, and then, the purified coix seed polysaccharide is subjected to vacuum freeze drying to obtain the white powder, namely the coix seed polysaccharide; and therefore, the preparation method is simple and the coix seed polysaccharide is high in yield.

A method of treating a tumor, comprising creating an elevated concentration of free radicals in said tumor and creating a magnetic field that traverses said tumor and that inhibits the recombination of said free radicals in said tumor, thereby increasing the rate of apoptosis of cancerous cells. A magnetic field of 0.1 mTesla to 10 mTesla is generally used for this purpose.

Use of nordihydroguaiaretic derivatives to suppress CDC-2 and survivin, stimulate apoptosis, and treat tumors.

The invention relates to a human reforming mouse ING4 (tumor growth inhibition factor) gene and recombinant adenovirus (adenovirus hominis 5 shape Ad-ING4-DeltaGFP), wherein preservation cooperation is Chinese typical culture preservation centre, preservation number is CCTCC-V200701. The invention also relates to a human reforming gene mutation technique, adenovirus transition carrier removing GFP and homologous recombinant adenovirus carrier. The ING4 gene and recombinant adenovirus carrier provide new immunodiagnosis and target therapeutic approach for treating neoplastic disease, development disease, immune disease, the other disease owing to abnormal expression of tumour growth inhibition factor ING4, special cancer of the lungs and leukocythemia, which is provided with a giant application prospect.

The invention discloses a cell electrochemical sensor for analyzing joint toxicity of fungaltoxin, belonging to the fields of analysis and detection of food quality. According to the cell electrochemical sensor, the sensitivity of the sensor is increased by virtue of electroplating gold nanoparticles, an in-vivo physiological living environment of cells is simulated by virtue of laminin, and a three-dimensional model is constructed by virtue of rat tail collagens so as to relatively truly reappear cell morphology; and the constructed cell electrochemical sensor can rapidly and sensitively respond to the influences caused by the fungaltoxin to human hepatoma carcinoma cells, equipment is convenient and rapid and low in production cost, and by combining with an electrochemical resistance value and a joint index method, the type and degree of a joint action of the fungaltoxin can be rapidly judged. The constructed portable cell electrochemical sensor is successfully applied to the toxicity analysis of the fungaltoxin in foods and has good application prospects in the analysis of the joint toxicity of the fungaltoxin.

The invention relates to a TPGS modified docetaxel liposome nano-drug delivery system, a preparation method and an application thereof. The TPGS modified docetaxel liposome nano-drug delivery system uses phospholipid and cholesterol as membrane materials, Surfactant TPGS modified liposomes and docetaxel (DTX) as anticancer drug were prepared by membrane dispersion ethanol injection ultrasonic dispersion reverse evaporation and freeze drying. The particle size of nano-doxetaxel liposomes modified by TPGS is 80-200 nm, the zeta potential is 0+30 mV or 0-30 mV, the encapsulation efficiency is 75-99%, with a drug loading of 3-15%. The in vitro cell experiment and in vivo pharmacodynamic experiment of the TPGS modified docetaxel liposome nano-drug delivery system prepared by the invention showthat the nano-drug delivery system can inhibit P. Overexpression of gp, decrease of drug efflux, increase of drug enrichment in tumor cells, increase of cytotoxicity and apoptosis rate, increase of tumor therapeutic effect and reversal of multidrug resistance.

The invention belongs to the medical and biotechnical fields and in particular relates to application of a mesenchymal stem cell in preparation of a medicine used for treating M5 type leukaemia. The mesenchymal stem cell provided by the invention is obtained by stimulating specific inflammatory factors TNF-alpha and IFN-gamma; the capability of the mesenchymal stem cell for inducing tumor cell apoptosis is realized by a tumor necrosis factor-related apoptosis inducing ligand TRAIL; and the mesenchymal stem cell is in vitro. By virtue of stimulation on TNF-alpha and IFN-gamma, the TRAIL expression capability of the mesenchymal stem cell is obviously improved, and anti-tumour capability is obviously enhanced; compared with chemical therapy, toxic and side effects in mesenchymal stem cell transplantation are lower; due to low immunogenicity of the mesenchymal stem cell, morbidity of graft versus host disease is also greatly reduced, clinical requirement is met, and a new thought is provided for stem cell transplantation therapy. The mesenchymal stem cell can be applied to preparation of the medicine used for treating the M5 type leukaemia.

The invention relates to the field of cytobiology and particularly discloses an efficient CIK cell culturing method by means of efficiently culturing the CIK cells through the steps of monocyte separation, culture bottle inoculation, culture bag inoculation and cell collection, adding the inducible factors such as IL-1, IL-2, IL-24, IFN-gamma, CD3AK, EGF during the culture process, inducing the peripheral blood mononuclear cell into the CIK cell and performing in vitro efficient amplification. After culturing for 10 days, the peripheral blood mononuclear cell with the initial cell number of 2*10<6> is induced and amplified to the 1*10<10> CIK cell, the CIK cell in vitro multiplication culture speed and the final obtained cell number can be effectively increased, besides, by adopting the CIK cell cultured by the method, the maximum apoptosis rates of the cervical cancer Hela cell and the myeloma Sp20 cell are 64.2% and 54.3%.

The invention relates to antitumor drugs and discloses anti-glioma drugs based on Venenum Bufonis extract and a preparation method thereof, the drugs being a bufotalin submicron emulsion and a bufotalin nanoparticle preparation, wherein the bufotalin submicron emulsion comprises Venenum Bufonis extract, medium chain triglyceride, a lecithin, poloxamer 188, glycerol, sodium oleate and injection water; the bufotalin nanoparticle preparation comprises Venenum Bufonis extract, glycerol monostearate, medium-chain fatty acid glyceride, oleic acid, a lecithin, poloxamer 188, sodium deoxycholate and injection water. Both the two preparations can combine with endothelial cells in cerebral blood capillaries, enabling the drugs to be transmitted into the brain through membranes or by means of adsorption, medication, endocytosis and transferring, cerebral targeting of the drugs is improved, and further increase of bufotalin in the brain is facilitated, and glioma resistance is achieved by inducing apoptosis and excessive autophagy of cells.

The invention relates to the technical field of medicaments, and discloses a transcatheter arterial chemoembolization embolism agent containing an autophagy inhibitor for treating liver cancer. The embolism agent consists of a chemotherapy medicament, the autophagy inhibitor and iodized oil, wherein the chemotherapy medicament is cis-platinum; the iodized oil is liquid iodized oil; and the autophagy inhibitor is selected from bafilomycin A1 or chloroquine. The bafilomycin A1 or the chloroquine can be used as a sensitizer of the chemotherapy medicament, and can increase the sensitivity of liver cancer cells to the chemotherapy medicament in a hypoxic ischemic microenvironment after embolism and enhance the anti-cancer effect of the chemotherapy medicament. Animal experiments show that the embolism agent can achieve good curative effect for treating middle and late primary liver cancers, obviously increase the apoptosis rate and the necrosis rate of tumor cells and remarkably reduce tumors so as to improve the curative effect of transcatheter arterial chemoembolization. The invention provides the embolism agent with good curative effect and low injury for the transcatheter arterial chemoembolization.

A method of treating cancer by administering a therapeutically effective amount of a compound represented by the following Formula (I), or salt, hydrate, or solvate thereof: wherein: n represents a number from 3 to 7; m represents a number from 1 to 2; R1 and R2 independently represent a hydrogen atom or are a substituted or unsubstituted, branched or unbranched or cyclic, alkyl provided that the total number of carbon atoms represented by R1 and R2 when taken together is no less than 5 and no greater than 10; or R1 and R2 together independently represent a cyclic alkyl group having no less than 3 or no more than 7 carbon atoms; R3 and R4 independently represent a hydrogen atom or a saturated or unsaturated, substituted or unsubstituted, branched or unbranched or cyclic, hydrocarbyl radical.

The invention relates to the technical field of biomedicine engineering and provides application of a reagent for inhibiting or down-regulating expression of a GTSE1 gene in preparation of a tumor radiotherapy sensitization drug, particularly application in preparation of a lung cancer radiotherapy sensitization drug. Experiments prove that GTSE1 knockdown promotes DNA damage of exposure to lung cancer cells, increases the radiosensitivity of three lung censer cells significantly and increases the apoptosis rate of the three lung cancer cells after exposure significantly with the increase of an exposure dose, and the cell survival rate of the three lung cancer cells is obviously lower than that of a normal lung cancer cell group. Therefore, the application provides a new exploration for improving the sensitivity of radiotherapy, contributes to radiotherapy sensitivity of malignant tumor and has certain clinical application prospects.

The invention relates to the technical field of anti-cancer drugs, in particular to a targeted drug delivery system for double-effect treatment and a preparation method and application of the targeteddrug delivery system. The targeted drug delivery system is prepared from the following components of a metal-organic framework and an anti-cancer drug, wherein the metal-organic framework has the cancer cell killing effect. The targeted drug delivery system for double-effect treatment has the advantages that various anti-cancer mechanisms are included, pertinence is high, and the drug loading capacity is large.

Provided is directed to the field of immunotherapy. Specifically, provided are compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the subject matter are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.

The invention relates to a portable high-voltage nanosecond squarer which belongs to a medicinal device for inducing cancer cell apoptosis by using a high-voltage nanosecond square wave pulse electric field. The portable high-voltage nanosecond squarer mainly comprises a power supply system, a high-voltage direct current module, a low-voltage power supply, a pulse forming system and a pulse shaping and counting system. The portable high-voltage nanosecond squarer has output pulses with highest amplitude of 15kV, pulse width adjustment range of 50ns-1us, rising edge gradient of reaching 10ns and controllable recurrence frequency of 0.2-15Hz; and the quantity of the output pulses of the portable high-voltage nanosecond squarer can be set. The portable high-voltage nanosecond squarer can be adjusted in multiple-parameters (pulse amplitude, pulse width, recurrence frequency, pulse quantity and the like), large-range and flexible and independent way, and is beneficial to researching the optimal window parameter of the cancer cell apoptosis and promoting the cancer cell apoptosis as well as improving the cancer treatment effect. Meanwhile, the portable high-voltage nanosecond squarer has compact and light structure, reliable work, simple operation and convenient popularization and application, and can be widely applied to the treatment of various cancers.

The present invention provides a method for treatment of leukemia comprising administration of arginase to a subject in need thereof. In one embodiment, the leukemia is lymphocytic or myeloid. In another embodiment, the leukemia is arsenic resistant. In a further embodiment, the arginase is pegylated recombinant human arginase. In another embodiment, the arginase can be administrated in combination with a second therapeutic agent such as Doxorubicin in the treatment of leukemia.

A method of treating a proliferative disorder, and a pharmaceutical composition for use in such a method, comprises administering to the patient a combination of an agonist of a death receptor and an antagonist of Egr-1. The death receptor agonist and the Egr-1 antagonist may be administered sequentially, separately or in combination

The invention provides a pulsed magnet field generator based on coil spherical focusing and IGBT single transistor parallel connection. The pulsed magnet field generator comprises a power supply system, a pulse current forming system, five coil spherical optimization focusing devices, a signal transformation system and a synchronized trigger module, and the switching power supply of the power supply system carry out voltage reduction on an alternating current power supply to form direct currents, is connected with the pulse current forming system, the signal transformation system and the synchronized trigger module and supplies power. The output ends of pulse generating modules M1-M5are connected with current carrying coils C1-C5 in the five coil spherical optimization focusing devices respectively. The electrical-optical converter J2 of the signal transformation system is respectively connected with the control ends of the pulse generating modules M1-M5. The output end of the synchronized trigger module is respectively connected with the electrical-optical converter J1 and the electrical-optical converter J2 of the signal transformation system. The pulsed magnet field generator is high in integration level, longer in service life and higher in work efficiency, the circuit size is greatly reduced, and the loss of the whole circuit is lowered.

The present invention discloses a model for evaluating an HR defect and its application. Based on a tumor individualized chemotherapy strategy, the method evaluates whether HR in gallbladder cancer cells is defective by using an existing HR-related indicator, and inhibits autophagy and PARP treatment according to normal HR or defective HR, improves the anti-tumor efficacy of a chemotherapy regimenFAM, and avoids the occurrence of resistance after multiple rounds of highly toxic medication for the patient. A multi-molecular marker used for detecting gallbladder cancer cells contains only 15 genes, is liable to clinical trials, reduces the cost of detection, and is not affected by the batch effect of experiments or the difference in the detection platforms, does not require data standardization between multiple samples before use, and is easy to use.

The invention discloses application of a CTNNB1 gene in porcine ovarian granulosa cells, and belongs to the technical field of cell engineering and gene engineering. According to the invention, the relative expression quantity of CTNNB1 mRNA in ovarian tissues, follicles with different sizes and granulosa cells of pigs in different periods, and the proliferation and apoptosis of the granulosa cells after overexpression and inhibition of CTNNB1 and the secretion of steroid hormones are detected. Results show that the CTNNB1 gene participates in promoting the proliferation of granulosa cells andthe secretion of estradiol and inhibiting the apoptosis of granulosa cells and the secretion of testosterone and progesterone, which indicates that the CTNNB1 gene participates in the development andmaturation of ovarian follicles of sows. Materials are accumulated for molecular mechanism research in the sow ovarian follicle development process.

The invention belongs to the field of Chinese medicine pharmacy, which relates to the application of pseudo-ginseng flower total saponin of active energy for preparing the drug for the treatment of hypertension, and the pseudo-ginseng flower total saponin is extracted from Chinese herbal medicine pseudo-ginseng flower. The in-vitro and in-vivo animal experimental results for the active energy of the invention show that the active energy can significantly lower blood pressure of spontaneously hypertensive rats (SHR), and improve the cell activity of vascular smooth muscle cell proliferation which is induced by ET-1, as well as increase the apoptosis rate of the vascular smooth muscle cell and the NO content inside the vascular smooth muscle cell; simultaneously the active energy can promote the expression of iNOS, and reduce Ca2 + concentration inside the vascular smooth muscle cell, as well as inhibite the oncogene c-mycmRNA expression of the vascular smooth muscle cell; thereby the pseudo-ginseng flower total saponin can be taken as raw material for preparing pharmaceutical preparation for the prevention of hypertension.

The invention discloses a new application of Rafoxanide. The influence of Rafoxanide to the skin cancer cell lines A375 and A431 is tested through a series of experiments, and the experiments indicate that the Rafoxanide is a target CDK4 / 6 inhibitor and can increase the number of cells of A375 and A431 stagnating in the G1 stage and reduce the number of the cells in the S stage; the apoptosis rate of A375 and A431 can be increased; the protein expression of the CDK 4 / 6, cyclinD and pho-CDK4 / 6 of the signal channel in the G1 stage of a cell cycle can be inhibited, a skin cancer-resistant effect is realized, and thus, the Rafoxanide can be used for preparing anti-cancer medicines for treating skin cancer; and since the Rafoxanide is a medicine resisting parasitic diseases already registered by FDA, the later clinical experiment cost is reduced, the medicine development time is shortened, and the cost and time for developing a new anti-cancer medicine are greatly saved.

The invention relates to a method for using yunnannogenin haulm saponin to produce medicine. Wherein, it uses the haulm of yunnannogenin as material, while yunnannogenin saponin I-IV can restrain the increment of leukemia cell K562 and HL60, while their IC50 value e lower than 10ug / ml; the saponin II can induce K562 and HL60 cell to dry externally, relative to the decrease of Bc1-2 / Bax ratio, which is the molecule target of leukocythemia resistance.

The invention relates to a preparation method of RGD cyclic peptide R8 peptide modified ergosterol and gefitinib combined compound liposome freeze-dried powder. The preparation method comprises the following steps: adding a freeze-drying protective agent into a pre-prepared RGD / R8-ERG / GEF-LIP liposome suspension in an external addition manner; and finally, preparing the freeze-dried powder of thecompound liposome by adopting a freeze-drying method. The RGD / R8-ERG / GEF-LIP lipidosome suspension is prepared by adopting the following method: firstly, preparing ERG / GEF-LIP, and then, preparing theRGD / R8-ERG / GEF-LIP lipidosome suspension by adopting a post-insertion method. According to the invention, an RGD / R8-ERG / GEF-LIP active drug-loading liposome drug delivery system is successfully constructed; ERG / GEF-LIP is used for investigating a freeze-drying process and a prescription, and after an optimal prescription process is screened out, the optimal prescription process is applied to RGD / R8-ERG / GEF-LIP for verification. An in-vitro test result of RGD / R8-ERG / GEF-LIP freeze-dried powder proves that the RGD / R8-ERG / GEF-LIP freeze-dried powder has a relatively strong tumor cell proliferation inhibition effect, the fluorescence uptake intensity and the good cell apoptosis rate.

The invention relates to the field of natural medicines, and provides application of tanshinone compounds to preparation of antitumor medicines. Tumors include lung cancer, prostate cancer, breast cancer, colon cancer, cervical cancer, liver cancer, pancreatic cancer, stomach cancer and the like. Experimental results show that the tanshinone compounds are concentration-dependent and time-dependent, can inhibit growth of tumor cells, and can significantly induce apoptosis of the tumor cells.

The invention belongs to the technical field of biology, and particularly relates to an in-vitro cytokine storm model and a construction method and application thereof. The construction system of the in-vitro cytokine storm model contains a TNF-alpha factor, an IL-1[beta] factor, an IL-6 factor and vascular endothelial cells. The in-vitro cytokine storm model is formed by the body. According to the in-vitro cytokine storm model construction method, vascular endothelial cells, TNF-alpha factors, IL-1[beta] factors and IL-6 factors are incubated together. The invention discloses application of an in-vitro cytokine storm model in screening of anti-cytokine release syndrome drugs. The invention relates to an application of an in-vitro cytokine storm model in preparing and screening anti-cytokine release syndrome drugs. The in-vitro cytokine storm model disclosed by the invention is obtained by jointly treating vascular endothelial cells through three factors, namely TNF-alpha, IL-1[beta] and IL-6, the in-vitro cytokine storm model with high cell apoptosis rate and obviously reduced cell activity can be prepared, and a better basis is provided for research on inflammatory response related to multiple factors.